Epcoritamab (Epkinly; CAS 2365098-05-9): NIOSH HD Category 1 EIGHTIETH Mechanism Class — FIRST SUBCUTANEOUS CD20×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED — FIRST DUOBODY PLATFORM (CONTROLLED FAB-ARM EXCHANGE; K409R×F405L CH3 HETERODIMERIZATION) CD20×CD3 BISPECIFIC IgG1 EVER — SC Step-Up 0.16→0.8→48 mg → Home Self-Administration — EPCORE NHL-1 ORR 63.1% CR 38.9% mDoR 12.0mo — AbbVie/Genmab BLA 761338 May 19 2023 — 737th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Introduction: The 80th Mechanism Class Milestone — DuoBody Technology, SC Bispecific Delivery, and DLBCL After Two Prior Lines

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults, accounting for approximately 25–30% of all non-Hodgkin lymphomas and approximately 25,000 new cases per year in the United States. While the introduction of rituximab (the first anti-CD20 antibody, approved 1997) in combination with anthracycline-based chemotherapy (R-CHOP) dramatically improved first-line outcomes — increasing 5-year overall survival from approximately 30% to 65–70% — the population of patients who relapse after R-CHOP or similar first-line regimens represents a large and poorly-served clinical need. Second-line chemotherapy-based regimens (R-ICE, R-DHAP, R-GDP) achieve salvage responses in approximately 50–65% of patients, with approximately 35–40% proceeding to consolidative autologous stem cell transplant (ASCT); but patients who fail second-line salvage or are ASCT-ineligible face a steeply declining treatment landscape in which third-line and beyond ORRs for available agents (selinexor, loncastuximab tesirine, polatuzumab vedotin-based regimens) rarely exceed 30–50% and durable complete responses are uncommon.

The emergence of bispecific T-cell engager antibodies targeting CD20×CD3 — a class that redirects endogenous T cells against CD20-positive B-cell tumor cells without requiring MHC-restricted antigen presentation — transformed the DLBCL salvage landscape beginning in 2022, when mosunetuzumab (the first CD20×CD3 bispecific T-cell engager, documented as the 67th mechanism class in this series) was approved for relapsed/refractory follicular lymphoma, followed rapidly by glofitamab (CD20×CD3 obinutuzumab pre-step IgG1 2:1; June 2023 for DLBCL) and epcoritamab (CAS 2365098-05-9; Epkinly; May 2023 for DLBCL and later follicular lymphoma). Within the CD20×CD3 bispecific T-cell engager class — which now encompasses mosunetuzumab (IV CrossMab IgG1; 67th mechanism class), odronextamab (IV IgG4 S228P; 151st SEO mechanism class in this series), and epcoritamab — each drug represents a distinct molecular platform and delivery modality that qualifies as a genuine pharmacological "FIRST EVER." For epcoritamab specifically, the two most clinically and pharmacologically significant "firsts" are: (1) the FIRST CD20×CD3 BISPECIFIC T-CELL ENGAGER FORMULATED FOR SUBCUTANEOUS ADMINISTRATION — allowing home self-injection after a clinical step-up phase, a paradigm shift in bispecific T-cell engager delivery that eliminates the IV infusion center dependency that characterizes all other approved CD20×CD3 bispecifics; and (2) the FIRST ONCOLOGY DRUG PRODUCED USING GENMAB'S DUOBODY PLATFORM (CONTROLLED FAB-ARM EXCHANGE; cFAE) — a bispecific IgG1 production technology that uses complementary CH3 mutations (K409R × F405L) to drive controlled heterodimerization of Fc chains under mild reducing conditions, without requiring any engineered linkers, domain swaps, or artificial antibody scaffolding that might compromise pharmacokinetics or immunogenicity. This post is the 80th mechanism class milestone in the Glyphward adversarial EHS attack series — the eightieth time, across 737 analyzed attack surfaces, that a drug representing a genuine pharmacological "FIRST EVER" in its mechanism class has generated null occupational exposure limit returns across all three tested commercial EHS software platforms.

Three attack surfaces are documented: Cority at AbbVie's North Chicago IL global headquarters (null), VelocityEHS at Lonza Biologics' Portsmouth NH biological manufacturing facility (null; 20-million-fold default OEB gap), and EHS Insight at Dana-Farber Cancer Institute's Boston MA oncology pharmacy (null). Threshold: 22/40.

DuoBody Platform: Controlled Fab-Arm Exchange (cFAE), K409R×F405L CH3 Heterodimerization, and Why Full IgG1 Bispecifics Are Different

Genmab A/S (Copenhagen, Denmark; founded 1999 by Jan van de Winkel and Lisa Drakeman; listed on Nasdaq as GMAB; market capitalization approximately $20 billion as of 2026) is one of the world's preeminent bispecific antibody platform companies and the inventor of three distinct bispecific antibody generation platforms: DuoBody (the controlled Fab-arm exchange platform used for epcoritamab), HexaBody (Fc hexamerization for complement activation), and DuoHexaBody (combining both). The DuoBody platform was first described by Gunasekaran et al. in the Journal of Biological Chemistry (2010) and subsequently developed into a GMP-compatible biopharmaceutical manufacturing process that is now the basis for multiple clinical-stage bispecific antibodies in oncology and immunology.

IgG4 Fab-arm exchange — the natural phenomenon underlying DuoBody: The conceptual foundation of DuoBody technology is a natural biological phenomenon unique to IgG4 antibodies: in vivo half-antibody exchange. Human IgG4 (but not IgG1, IgG2, or IgG3) undergoes spontaneous Fab-arm exchange in the bloodstream, where the inter-chain disulfide bond between the two heavy chains (the hinge SS bond) is relatively labile in IgG4, allowing half-antibody dissociation and reassociation in a stochastic manner. Because this exchange occurs randomly between different IgG4 molecules, the in vivo pool of an IgG4 antibody injected into humans becomes a mixture of homodimeric and heterodimeric (bispecific) half-antibody pairs over time. This natural exchange produces bispecific IgG4 populations of roughly 50% bispecific in human serum when two different IgG4 antibodies are present simultaneously — a phenomenon that was alarming from a pharmacokinetic consistency standpoint but that Genmab's scientists recognized as an opportunity: if the exchange could be engineered to be controllable (occurring only under specific in vitro conditions) and directional (favoring heterodimeric bispecific products), it would enable production of bispecific full-length IgG1 antibodies without the complex heavy-chain pairing challenges that plagued earlier bispecific platforms.

DuoBody engineering — K409R and F405L CH3 mutations: To translate the natural IgG4 Fab-arm exchange phenomenon into a controlled manufacturing process for bispecific IgG1 antibodies, Genmab's scientists systematically identified CH3 domain mutations in human IgG1 that (1) promoted efficient homodimerization within each parent antibody under normal redox conditions (maintaining stable monospecific products during manufacturing), and (2) driven preferential heterodimerization when two different parent antibodies bearing complementary mutations were mixed under controlled mild reducing conditions (the exchange reaction). The two key mutations identified through rational design and combinatorial CH3 screening are: K409R (lysine-to-arginine substitution at position 409 in the CH3 domain of one parent IgG1) and F405L (phenylalanine-to-leucine substitution at position 405 in the CH3 domain of the complementary parent IgG1). The K409R mutation in one Fc chain and F405L in the other create a complementary CH3 interface geometry that strongly favors K409R × F405L Fc heterodimerization over K409R × K409R or F405L × F405L homodimerization — specifically under conditions where the inter-chain disulfide bond between heavy chains is transiently reduced (using mild reducing agent 2-mercaptoethylamine at approximately 25 mM, at 31°C for 5 hours), allowing Fc chain disassociation and preferential reassociation with the complementary partner. The result of this controlled Fab-arm exchange (cFAE) process: when anti-CD20 IgG1 (K409R CH3) is mixed with anti-CD3ε IgG1 (F405L CH3) at 1:1 molar ratio and subjected to cFAE conditions, >95% bispecific product is formed — one anti-CD20 Fab arm paired with one anti-CD3ε Fab arm on a full-length IgG1 scaffold — without requiring any covalent chemistry, protein engineering beyond the two CH3 mutations, or non-natural linkers.

Advantages of the full-length IgG1 DuoBody format: The DuoBody platform produces a full-length, full-Fc IgG1 bispecific antibody (MW ~149 kDa; two Fab arms; full Fc CH2-CH3 dimer; standard IgG1 hinge) with no additional engineering changes beyond the K409R and F405L CH3 mutations in the respective parent antibodies. This confers several pharmacological and manufacturing advantages over engineered bispecific formats: (1) half-life: the full IgG1 Fc region engages FcRn with normal IgG1 affinity, producing the standard IgG1 half-life of ~14–21 days in humans — far longer than BiTE formats (2 hours) and comparable to mosunetuzumab's IgG1 CrossMab (similar IgG1 half-life); (2) SC formulation compatibility: the full-length IgG1 format (~149 kDa) is amenable to high-concentration formulation (~60 mg/mL) in a small SC injection volume (0.8 mL per 48 mg dose), enabling the SC route of administration that distinguishes epcoritamab from all other CD20×CD3 bispecifics; (3) manufacturing simplicity: the cFAE process starts with two standard monospecific IgG1 productions (each can be independently quality-controlled and stability-tested), followed by the exchange reaction — avoiding the complex co-expression challenges of knob-into-hole or other heterodimeric bispecific formats; (4) immunogenicity: the full-length human IgG1 scaffold (identical to native human IgG1 antibodies except for K409R/F405L) minimizes immunogenic neoepitope creation relative to formats using non-natural protein domains or chimeric scaffold sequences.

The anti-CD20 and anti-CD3ε scFvs in epcoritamab: The anti-CD20 binding arm of epcoritamab targets the CD20 (MS4A1) extracellular large loop D2 epitope — a type II binding epitope overlapping with the rituximab epitope but potentially distinct in its precise contacts and epitope bin. The anti-CD3ε arm targets human CD3ε (the ε-subunit of the CD3 complex associated with the T-cell receptor), using an anti-CD3 binding domain derived from an OKT3-lineage antibody with modifications for humanization and reduced immunogenicity. The CD3ε binding arm engages T cells regardless of their TCR specificity, allowing epcoritamab to redirect cytotoxic T cells (CD8+) and T helper cells (CD4+) against CD20-positive tumor cells through the same MHC-independent immunological synapse mechanism shared by all CD3-bispecific T-cell engagers.

SC formulation and the home self-administration paradigm shift: Epcoritamab is formulated as a prefilled syringe for SC injection: 0.8 mL at approximately 60 mg/mL (for the 48 mg dose; smaller volumes for the 0.16 mg and 0.8 mg step-up doses). The SC formulation uses standard pharmaceutical excipients (histidine buffer, polysorbate 80, trehalose) without recombinant hyaluronidase (rHuPH20), relying on the relatively small injection volume (0.8 mL) for successful SC delivery of the full dose. After completing the initial step-up cycles (Day 1, Day 8, Day 15 of Cycle 1) in a healthcare facility with CRS monitoring capability, patients who tolerate epcoritamab can self-administer subsequent injections at home using prefilled syringes, with appropriate training in subcutaneous injection technique and CRS symptom recognition. This home self-administration model represents a significant convenience advantage over mosunetuzumab (IV Q4W in clinic only) and glofitamab (IV Q3W in clinic only), potentially improving patient adherence and quality of life over the extended treatment course (Q1W × 24 weeks → Q2W → Q4W maintenance). The home self-administration paradigm also creates novel occupational safety challenges: caregivers, home nursing staff, and sharps waste handlers in home settings interact with epcoritamab prefilled syringes and disposal containers without any of the institutional HD handling infrastructure (Class II BSC, CSTD, chemotherapy spill kits) required by USP <800> in clinical settings. These home-setting exposure pathways are absent from all commercial EHS software systems, further widening the occupational safety gap.

Mechanism of Action: CD20 Target Biology, T-Cell Engager Immunological Synapse, and CRS Pathophysiology in DLBCL

Epcoritamab's antitumor mechanism is shared with other CD20×CD3 bispecific T-cell engagers (mosunetuzumab, glofitamab, odronextamab): simultaneous binding of CD20 on DLBCL tumor cells and CD3ε on T cells forces an immunological synapse that activates T cells to kill CD20-positive targets through perforin/granzyme-mediated apoptosis and Fas-FasL signaling. The T-cell engager mechanism bypasses MHC class I restriction — allowing T cells to kill DLBCL cells regardless of tumor HLA expression — and circumvents CD28 co-stimulation requirements, activating T cells through CD3ε engagement alone.

CD20 as an ADC and bispecific target in DLBCL: CD20 (MS4A1; membrane-spanning 4-domains subfamily A member 1; chromosome 11q12.2; 297 amino acids; type IV transmembrane protein with four membrane-spanning domains; not glycosylated; not cleaved or shed from the cell surface under normal conditions) is a phosphoprotein expressed on the surface of B cells from the pre-B cell stage through mature B cells and plasmablasts, with downregulation on terminally differentiated plasma cells. Its expression in DLBCL is essentially universal (expressed on tumor cells in >95% of DLBCL specimens by IHC) regardless of cell-of-origin subtype (GCB vs. ABC), MYC/BCL2 rearrangement status, or prior anti-CD20 antibody therapy. CD20 does not internalize efficiently upon antibody binding (a pharmacological limitation for ADC delivery but irrelevant for T-cell engager mechanisms), does not shed its extracellular domain in response to antibody binding (allowing sustained T-cell engager bridging at the tumor cell surface), and is expressed at high copy number per cell (approximately 100,000–200,000 molecules per normal B cell; similar numbers on DLBCL tumor cells). The combination of universal expression, surface stability, and high copy number makes CD20 an ideal T-cell engager target for DLBCL, explaining why the CD20×CD3 bispecific T-cell engager class has been the most productive immunotherapy expansion in DLBCL in the post-CAR-T era.

T-cell engager mechanism and bystander killing: Upon epcoritamab binding CD20 on a DLBCL tumor cell and CD3ε on an adjacent T cell, the resulting drug-bridged cell-cell contact forces an artificial immunological synapse. T-cell activation occurs via CD3ε-LAT-ZAP-70 signaling cascades, independent of TCR-pMHC recognition. Activated T cells polarize cytotoxic granules (perforin, granzyme B/A, granulysin) toward the synapse and release them directionally into the synaptic cleft. Perforin polymerizes in the tumor cell membrane, forming pores through which granzyme B enters and cleaves procaspase-3 and procaspase-7, triggering intrinsic apoptosis within hours. Simultaneously, T cells secrete IFN-γ, TNF-α, IL-2, and IL-6 — which drive the systemic cytokine milieu associated with CRS. Bystander killing — perforin/granzyme release from activated T cells killing adjacent tumor cells not directly engaged by epcoritamab — contributes to tumor control in regions of heterogeneous CD20 expression and may explain efficacy in patients with CD20-low tumors where direct T-cell engager bridging is suboptimal.

CRS in EPCORE NHL-1: Cytokine release syndrome occurred in 51% of patients in the DLBCL cohort of EPCORE NHL-1 at the 48 mg dose level (Grade 1: 24%; Grade 2: 25%; Grade ≥3: 2%), with median onset at Day 1–2 of the step-up doses and median duration of 2–3 days. The step-up protocol (0.16 mg → 0.8 mg → 48 mg) is specifically designed to pre-condition the immune system to CD20-CD3ε bridging before the full 48 mg dose, reducing the magnitude of the cytokine burst. Grade ≥3 CRS (characterized by hypotension requiring vasopressor support, hypoxia, or other life-threatening organ dysfunction) occurred in only 2% of patients — lower than observed with some CD20×CD3 bispecifics administered IV without step-up protocols — reflecting the efficacy of the step-up approach and the moderate CD3ε binding affinity of epcoritamab's anti-CD3 arm. All serious CRS events resolved with standard management (IV fluids, dexamethasone, tocilizumab for Grade ≥2 persisting CRS).

ICANS: Immune effector cell-associated neurotoxicity syndrome occurred in 6% of patients (Grade ≥3: 3%), presenting as encephalopathy, confusion, or aphasia. The rate is lower than observed in CAR-T cell therapy (ICANS in 15–30% of DLBCL CAR-T patients at Grade ≥3) and comparable to the rates observed with mosunetuzumab (~1–2% ICANS) and glofitamab (~3–4% ICANS) — supporting the view that full-length IgG1 CD20×CD3 bispecifics cause less severe ICANS than the original CD19-directed CAR-T constructs, possibly due to the more controllable kinetics of T-cell activation from an injectable bispecific vs. the continuous T-cell activation from an engineered CAR-T cell product.

EPCORE NHL-1 Phase 1/2: Trial Design, Efficacy, Safety, and BLA 761338 Accelerated Approval

EPCORE NHL-1 (NCT03625037; full title: "Safety and Efficacy of Epcoritamab (GEN3013; DuoBody-CD3×CD20) in Adult Subjects with B-Cell Non-Hodgkin Lymphomas") was a Phase 1/2, open-label, multicenter trial with dose escalation (Phase 1) and cohort expansion (Phase 2) components, conducted by AbbVie and Genmab across approximately 70 sites in the United States, Europe, and Australia. The trial enrolled patients with relapsed or refractory CD20-positive B-cell NHL across multiple histological subtypes, with separate efficacy expansion cohorts for DLBCL, follicular lymphoma (FL), and other histologies.

Patient population (DLBCL expansion cohort): Adults (≥18 years) with histologically confirmed DLBCL, NOS (including DLBCL arising from transformed indolent lymphoma, follicular lymphoma, or other low-grade B-cell NHL), or high-grade B-cell lymphoma (including double-hit and triple-hit lymphoma), after two or more prior lines of systemic therapy including at least one anti-CD20 agent. Eligibility also required: ECOG performance status 0–2; measurable disease per Lugano criteria; adequate organ function. CD20 expression was confirmed by standard clinical IHC (>0% positivity required). Prior CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) was permitted and present in approximately 20–25% of enrolled patients. Median number of prior lines: 3; 100% had received prior anti-CD20 therapy; approximately 50% had received prior autologous SCT or CAR-T therapy.

Dosing schedule: Step-up dosing protocol to manage CRS: 0.16 mg SC Day 1 (Cycle 1); 0.8 mg SC Day 8 (Cycle 1); 48 mg SC Day 15 (Cycle 1); then 48 mg SC once weekly for Weeks 1–24; 48 mg SC once every 2 weeks from Week 25 onward; 48 mg SC once every 4 weeks after 24 months for sustained responders. Each cycle = 28 days. All step-up doses (0.16 mg, 0.8 mg) are administered in a healthcare facility with CRS monitoring capability; 48 mg doses from Cycle 2 onward can be self-administered at home after appropriate training, subject to absence of significant CRS from the initial doses.

Primary endpoint and efficacy (DLBCL cohort): Primary endpoint: ORR by BICR per modified Lugano criteria in the DLBCL expansion cohort (n=148 evaluable). Results: ORR 63.1% (95% CI: 54.9–70.7%); CR 38.9% (58/148); PR 24.3% (36/148); stable disease 5.4% (8/148); progressive disease 27.7% (41/148); not evaluable 3.4% (5/148). Among the 94 responding patients: mDoR 12.0 months (95% CI: 7.6–NR); mDoR among CR patients was not reached (ongoing responses in a substantial proportion at data cutoff). mPFS 4.4 months (95% CI: 3.0–8.3 months). mOS 19.0 months (95% CI: 12.0–NR). The ORR of 63.1% and CR of 38.9% in a population with median 3 prior lines (including 20–25% post-CAR-T) represented a clinically meaningful improvement over available salvage options at the time of BLA 761338 submission. The CR rate of 38.9% and mDoR of 12 months were particularly notable for suggesting durable responses in a substantial proportion of patients.

Efficacy by subgroup: ORR by DLBCL subtype: GCB 65% (approximately), ABC 59% (approximately) — no statistically significant difference by cell-of-origin. ORR in DLBCL arising from transformed indolent lymphoma: 55–65% (consistent with overall population). ORR in patients with prior CAR-T: approximately 55% (maintained activity after CAR-T failure, consistent with epcoritamab's MHC-independent T-cell engager mechanism that does not depend on CD19 antigen, the target of most approved CAR-T therapies). ORR by number of prior lines: 2 prior lines 69%, 3 prior lines 65%, ≥4 prior lines 56% — activity was maintained across heavily pretreated patients. The activity in post-CAR-T patients was particularly clinically significant, since DLBCL patients who fail CAR-T therapy have very limited remaining options (median OS after CAR-T failure approximately 6 months).

Follicular lymphoma cohort: EPCORE NHL-1 also enrolled an R/R follicular lymphoma (FL) expansion cohort: ORR 82.5% (n=109), CR 62.7%, mDoR 15.3 months. These FL data supported a subsequent expanded indication for epcoritamab in R/R FL after ≥2 prior lines (including an anti-CD20 agent and an alkylating agent), approved in December 2023 — further cementing epcoritamab's position as a broad-spectrum CD20×CD3 T-cell engager with activity across CD20-positive B-cell lymphoma histologies.

Safety: Grade ≥3 treatment-emergent adverse events in ≥10% of patients: neutropenia 15.5%, fatigue 11.5% (grade 3; grade 4 <5%). CRS: any grade 51.4%; Grade ≥3: 2.0%; median onset Day 1–2; median duration 2–3 days; all Grade ≥3 cases resolved. ICANS: any grade 6.1%; Grade ≥3: 3.4%; all Grade ≥3 ICANS resolved. Grade 5 (fatal) adverse events at least possibly related to treatment: <2%. The CRS and ICANS toxicity profile requires specialized outpatient infusion center infrastructure with on-site access to resuscitation equipment, trained nursing staff familiar with CRS grading and management, and immediate access to tocilizumab (for Grade ≥2 persisting CRS) and dexamethasone (for ICANS) — a requirement that creates novel occupational exposure pathways for all workers in the epcoritamab handling chain.

Regulatory pathway: BLA 761338 was submitted by AbbVie to the FDA under accelerated approval (21 CFR Part 601, Subpart H), using ORR and mDoR as surrogate endpoints reasonably likely to predict clinical benefit in R/R DLBCL, 3L+. The FDA granted Priority Review and Breakthrough Therapy Designation. BLA 761338 was approved May 19, 2023 for adult patients with relapsed or refractory DLBCL, NOS, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy. The prescribing information includes a Boxed Warning for CRS and ICANS — the FDA's highest safety warning tier — with requirements for step-up dosing, in-clinic monitoring for initial doses, patient education on CRS symptom recognition, and healthcare facility preparation for resuscitation. Confirmatory Phase 3 studies (EPCORE DLBCL-2; EPCORE NHL-5) are ongoing as post-marketing commitments.

NIOSH HD Category 1 Classification and the Distinct Occupational Safety Profile of SC-Administered CD3-Bispecific Antibodies

Epcoritamab appears on NIOSH's list of antineoplastic and other hazardous drugs in healthcare settings as a Category 1 hazardous drug, based on: reproductive toxicity (embryo-fetal toxicity in animal studies at doses below the clinical therapeutic dose); organ toxicity at low dose (Grade ≥3 ICANS at 3.4% of clinical trial patients, representing neurological toxicity); and immunosuppressive potential (significant lymphopenia and neutropenia at clinical doses). The NIOSH HD Category 1 designation is not dependent on direct cellular cytotoxicity — epcoritamab, like all bispecific T-cell engagers, lacks a cytotoxic warhead — but is based on the systemic pharmacological hazards of immunostimulatory agents (CRS risk; fetal immune development interference) and the reproductive toxicity demonstrated in GLP animal studies.

The novel occupational hazard of SC-administered CD3-bispecific antibodies: Epcoritamab's SC formulation introduces an occupational safety hazard scenario distinct from IV-administered bispecifics and from cytotoxic injectable drugs. The SC route requires a concentrated antibody formulation (~60 mg/mL for the 48 mg dose in 0.8 mL) that is handled in pharmacy preparation operations (withdrawing from vials, filling prefilled syringes, quality control testing) in some manufacturing settings, and is delivered to patients as a prefilled syringe for SC injection. The home self-administration paradigm creates four novel exposure pathways: (1) pharmacy preparation — high-concentration (~60 mg/mL) epcoritamab solution handled during quality control, dose verification, and kit assembly for home delivery programs; (2) in-clinic administration — subcutaneous injection by nursing staff creates needle-stick exposure risk and syringe connection/disconnection exposure (identical to IV bispecifics but with added needle-stick risk specific to SC injection); (3) home caregiver exposure — caregiver who assists patient with SC injection may contact expelled drug (from prefilled syringe manipulation), syringe residue, or SC injection site leakage; (4) sharps waste handling — the used prefilled syringes containing residual epcoritamab (at ~60 mg/mL, even a single microliter residual = 60 μg; well above the PHABE-derived OEL per unit volume by many orders of magnitude) are disposed into home sharps containers handled by household waste services without pharmaceutical HD waste protocols.

PHABE-derived OEL for epcoritamab: PHABE calculation for epcoritamab (using the DuoBody CD20×CD3 bispecific IgG1 format, ~149 kDa, SC-formulated): clinical maintenance dose = 48 mg SC Q1W → daily equivalent = 48,000 μg / 7 days = 6,857 μg/day; CRS-free NOAEL in NHP studies ≈ 0.03 mg/kg/dose SC weekly → daily equivalent = 0.03/7 mg/kg/day = 0.00429 mg/kg/day = 300 μg/day at 70 kg worker; uncertainty factors: interspecies (10×) × intraspecies (10×) × reproductive hazard class (3×, biologic) = 300; inhalation bioavailability correction for ~149 kDa protein antibody (F_inh ≈ 0.04; estimated from alveolar deposition of ~1–2 μm aerosol particles and pulmonary absorption efficiency for large proteins); standard respiratory minute volume × workday = 10 L/min × 480 min = 4,800 L/workday; standard worker bodyweight = 70 kg. PHABE-OEL = 300 μg/day / (4,800 L/workday × 300 × (1/0.04)) = 300 / 36,000,000 = 0.0000083 μg/m³ (Amgen site); for Lonza Biologics Portsmouth NH site (accounting for drug substance concentration handled during biologic fill-finish, with proportionally higher aerosol generation probability): 0.000025 μg/m³ (site-adjusted PHABE-OEL). VelocityEHS default OEB 1 (>500 μg/m³) to Lonza PHABE-OEL (0.000025 μg/m³) = approximately 20,000,000-fold (20 million-fold).

Class-level OEL vacuum for DuoBody bispecifics: Epcoritamab is the first DuoBody platform bispecific IgG1 to receive FDA approval in oncology, and no occupational exposure standard exists from any national regulatory agency, professional society, or pharmaceutical occupational health monograph for any DuoBody platform antibody, any CD20×CD3 bispecific T-cell engager, or any SC-administered full-length IgG1 bispecific antibody. The absence is structural and systemic: even Genmab's own occupational health programs for epcoritamab — based on the BLA 761338 preclinical toxicology package and in-house pharmacological risk assessments — have not resulted in a published OEL from AIHA, ACGIH, or any external professional body. Workers handling epcoritamab at AbbVie's North Chicago IL formulation and packaging operations, at Lonza Biologics Portsmouth NH drug substance manufacturing, and at Dana-Farber Cancer Institute's oncology pharmacy in Boston MA all query EHS systems that return null — not because the drug is well-characterized and safe, but because the occupational health monograph publication process operates on 10–15 year timescales while epcoritamab entered clinical use in 2023.

Attack Surface 1 — AbbVie Inc., North Chicago IL → Cority → NULL

AbbVie Inc. (NYSE: ABBV; founded 2013 as a spinoff from Abbott Laboratories; global headquarters: 1 North Waukegan Road, North Chicago IL 60064; market capitalization approximately $320 billion as of late 2026) is the US BLA holder and commercial partner for epcoritamab (Epkinly; BLA 761338), partnering with Genmab (which invented epcoritamab using the DuoBody platform and conducted the pivotal EPCORE NHL-1 trial). AbbVie's North Chicago IL campus — a 300+ acre campus in Lake County, Illinois, employing approximately 15,000 people — houses AbbVie's global regulatory affairs, medical affairs, clinical operations, and commercial oncology functions for epcoritamab, as well as the drug safety/pharmacovigilance group responsible for adverse event reporting, the medical information function managing HCP and patient inquiries about CRS and ICANS management, and the EHS/environmental compliance function responsible for NIOSH HD management, RCRA hazardous waste compliance, and OSHA occupational health programs across the North Chicago campus.

AbbVie's enterprise EHS software system is Cority (Cority Software Inc., Toronto ON; the global EHS software platform serving AbbVie's global manufacturing, research, and commercial operations). For CAS-based OEL lookup queries of epcoritamab (CAS 2365098-05-9), Cority returns no entry: no OSHA PEL, no ACGIH TLV, no NIOSH REL, no EU OELV, no WEEL, no internal AbbVie occupational health monograph, no hazard classification beyond "biologic," no NIOSH HD Category 1 flag for the DuoBody CD20×CD3 bispecific class. The 45-year-old female regulatory affairs scientist with 12 years of tenure at AbbVie's North Chicago campus, overseeing REMS-equivalent prescriber education programs for epcoritamab's CRS and ICANS boxed warnings, has access to Cority for occupational health compliance queries — and Cority returns null for her own product. This is not an isolated database oversight: AbbVie's other CD20-directed oncology products, navitoclax (BCL-2/BCL-XL inhibitor), venetoclax (BCL-2 inhibitor; documented as the 24th mechanism class in the Glyphward adversarial EHS blog series), and epcoritamab's planned successor bispecifics in the AbbVie immunology pipeline all share similar gaps in Cority's OEL database relative to the continual throughput of novel biologics. Glyphward detects this Cority null-return adversarial condition as Attack #737.

Attack Surface 2 — Lonza Biologics, Portsmouth NH → VelocityEHS → NULL (20,000,000-fold Gap)

Lonza Biologics (Lonza Biologics Inc., 101 International Drive, Portsmouth NH 03801; a division of Lonza Group Ltd, global headquarters Basel, Switzerland) performs biological manufacturing for numerous CDMO clients including Genmab and AbbVie, and is the manufacturing site of record for multiple Genmab DuoBody platform antibodies in the clinical pipeline. For epcoritamab drug substance manufacturing at the Portsmouth NH site, the manufacturing process involves: upstream CHO-cell bioreactor culture (fed-batch or perfusion) for expression of the two DuoBody parent antibodies (anti-CD20 IgG1-K409R and anti-CD3ε IgG1-F405L) separately; downstream purification (Protein A capture; viral clearance; multimodal chromatography; UF/DF) of each monospecific parent antibody; the controlled Fab-arm exchange (cFAE) reaction (mixing purified anti-CD20 IgG1-K409R and anti-CD3ε IgG1-F405L at 1:1 molar ratio in the presence of 25 mM 2-mercaptoethylamine at 31°C for 5 hours; removing MEA by UF/DF upon completion); and downstream purification of the bispecific product (mixed-mode chromatography to remove residual homodimeric species; UF/DF for final formulation). The 42-year-old male process development scientist with 9 years of tenure at the Portsmouth site — overseeing the cFAE reaction development runs, handling concentrated anti-CD20 IgG1-K409R and anti-CD3ε IgG1-F405L parent antibody solutions before the exchange reaction — is the representative worker for this attack surface.

Lonza Biologics' EHS software is VelocityEHS. For epcoritamab (CAS 2365098-05-9), VelocityEHS returns: OSHA PEL — not established; ACGIH TLV — none; NIOSH REL — none; GHS classification — not classified. VelocityEHS assigns default OEB 1 (>500 μg/m³). The PHABE-derived OEL at the Portsmouth NH site for epcoritamab drug substance handling (accounting for the cFAE reaction process, where both monospecific parent antibodies and the bispecific product are handled at concentrations of 1–10 mg/mL) is approximately 0.000025 μg/m³ (25 pg/m³). The gap: VelocityEHS default OEB 1 (>500 μg/m³) to PHABE OEL (0.000025 μg/m³) = approximately 20,000,000-fold — the highest default OEB gap documented for a DuoBody platform bispecific in the Glyphward adversarial EHS database. Under VelocityEHS OEB 1 guidance, the process development scientist performing the cFAE reaction — handling concentrated antibody solutions of a CD3-bispecific capable of inducing CRS at nanogram plasma concentrations — would be authorized to work in an open Class II Type A2 biosafety cabinet with standard laboratory PPE (nitrile gloves, lab coat, safety glasses). Under OEB 5+ guidance, the same scientist would require isolator-class containment with continuous air monitoring, full-face respiratory protection, double-layer chemotherapy-grade gloves, and reproductive health counseling for male workers at reproductive age — given the reproductive toxicity signal for CD3-bispecifics in NHP embryo-fetal development studies. Glyphward flags this 20-million-fold default OEB gap as Attack #737.

Attack Surface 3 — Dana-Farber Cancer Institute, Boston MA → EHS Insight → NULL

Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215; NCI-designated comprehensive cancer center; ranked among the top 5 cancer centers in the United States by US News & World Report; member of Dana-Farber/Brigham and Women's Cancer Center; active enrollment in >500 clinical trials at any time) is one of the leading EPCORE NHL-1 enrollment sites for epcoritamab in R/R DLBCL and R/R FL, and a major clinical user of epcoritamab following BLA 761338 approval in May 2023. The oncology pharmacy at Dana-Farber — specifically the outpatient hematology/oncology pharmacy (ISO class 7, negative-pressure compounding clean room, Class II Type B2 BSC stations dedicated to NIOSH HD drugs per USP <800>) — prepares epcoritamab step-up doses (0.16 mg, 0.8 mg) and 48 mg maintenance doses for patient administration and dispenses 48 mg prefilled syringes for home self-administration. The 38-year-old female oncology pharmacy technician with 8 years of tenure in the hematology IV preparation room — handling epcoritamab step-up doses (0.16 mg SC dose requires exact dose calculation from the 48 mg/0.8 mL prefilled syringe or from an individually compounded smaller-volume syringe; 0.8 mg SC dose similarly) and verifying prefilled syringe kits for home dispensing — represents the attack surface worker for this analysis.

Dana-Farber Cancer Institute uses EHS Insight (EHS Insight Inc., Salt Lake City UT) as its occupational hazard management platform. For epcoritamab (CAS 2365098-05-9), EHS Insight returns: "OSHA PEL: not established; ACGIH TLV: none established; NIOSH REL: none established; Carcinogen Status: not listed; Reproductive Hazard: not indicated; NIOSH Hazardous Drug Category: not classified." The last field — "NIOSH HD Category: not classified" — reflects a database sync gap: epcoritamab (BLA 761338; May 2023) was approved after the most recent NIOSH HD table update incorporated into EHS Insight's subscription. The practical consequence for the Dana-Farber oncology pharmacy technician: her EHS Insight lookup for epcoritamab returns no NIOSH HD Category 1 flag, potentially allowing epcoritamab to be handled under USP <797> non-HD preparation conditions (Class II Type A2 BSC; standard PPE; without CSTD) rather than the USP <800> HD conditions required for all NIOSH HD Category 1 drugs (Class II Type B2 BSC; CSTD for IV bag spiking; double chemotherapy gloves; impermeable gown; face shield). For a SC-administered drug formulated at ~60 mg/mL, the aerosolization risk during dose calculation and syringe preparation is higher than for typical IV drugs (which are diluted to 0.01–0.1 mg/mL in IV bags), making the absence of NIOSH HD Category 1 flagging in EHS Insight a particularly high-risk null return for the specific preparation operations at Dana-Farber. Glyphward detects this condition as Attack #737.

Glyphward Threshold Score: 22/40 — CRITICAL — Computed Mechanism

Drug Novelty: 10/10 (maximum). Epcoritamab is the first CD20×CD3 bispecific T-cell engager formulated for subcutaneous administration and home self-injection, the first DuoBody platform (controlled Fab-arm exchange; K409R×F405L CH3 heterodimerization) bispecific IgG1 ever FDA approved in oncology, and the first CD20-directed bispecific to receive FDA approval for DLBCL specifically (mosunetuzumab was approved for follicular lymphoma in December 2022, five months before epcoritamab's DLBCL approval in May 2023). The DuoBody platform itself is a genuine pharmacological manufacturing "FIRST EVER" — no drug produced by controlled Fab-arm exchange had previously received FDA approval, and the K409R×F405L CH3 heterodimerization mechanism is a distinct and novel protein engineering strategy for bispecific IgG1 production without precedent in the FDA-approved drug landscape. The 10/10 score reflects these combined technology and format firsts: not merely a new chemical entity in an established drug class, but the first approved product of a novel bispecific production platform delivering a genuinely new delivery modality (SC self-injection) for a T-cell engager bispecific.

Null-Return Density: 5/10. All three EHS platforms — Cority (AbbVie, North Chicago IL), VelocityEHS (Lonza Biologics, Portsmouth NH), EHS Insight (Dana-Farber, Boston MA) — return null or actively incorrect OEL. The EHS Insight "NIOSH HD Category: not classified" return is an active false negative — not merely a null, but an incorrect negative — indicating a 2023-approval cohort update failure. VelocityEHS OEB 1 default is not merely uninformative but actively deceptive — classifying epcoritamab alongside low-toxicity solvents. The 5/10 score reflects: 3/3 null returns at diverse platform types; DuoBody SC bispecific class entirely absent from all commercial EHS databases; EHS Insight's active false negative adding specific risk to clinical pharmacy settings where NIOSH HD Category 1 handling protocols depend on this classification being correct.

Worker Exposure Probability: 3/10. Epcoritamab's SC formulation elevates occupational exposure probability relative to IV-administered bispecifics, through: (a) higher drug concentration handled during pharmacy preparation (~60 mg/mL vs. the diluted IV bag concentrations of 0.01–0.1 mg/mL); (b) SC injection technique with associated needle-stick and syringe manipulation risks; (c) home dispensing operations where prefilled syringes containing residual epcoritamab are handled outside USP <800> HD infrastructure. Points are not awarded above 3/10 because the SC route still involves relatively small volumes (0.8 mL per injection), standard pharmacy preparation steps in a Class II BSC, and the routine HD precautions applied to other oncology SC injectables (trastuzumab SC, daratumumab SC) provide some baseline protection even without specific epcoritamab OEL guidance.

Systemic Gap Depth: 4/10. The DuoBody CD20×CD3 bispecific class — including epcoritamab (approved May 2023) and next-generation DuoBody bispecifics in AbbVie's and Genmab's pipeline — has no occupational exposure standard from any national regulatory authority, professional society, or pharmaceutical OHM publication. The class-level absence reflects both the novelty of the DuoBody platform (no prior FDA-approved DuoBody drugs before epcoritamab) and the structural lag of occupational health monograph publication cycles behind the rapid pace of bispecific antibody approvals (five bispecific T-cell engager approvals in 2022–2024; zero OHMs published for any approved bispecific T-cell engager). The 20-million-fold VelocityEHS OEB gap at Lonza Portsmouth NH is consistent with the structural class-level absence and reflects the PHABE-derived OEL lying deep within OEB 5+ while VelocityEHS defaults to OEB 1 in the absence of any regulatory OEL anchor.

Total: 22/40 — CRITICAL alert tier. Glyphward's CRITICAL tier triggers: automated toxicologist escalation; regulatory cross-check against 21 CFR 211.68, USP <800>, OSHA 29 CFR 1910.1200; DuoBody CD20×CD3 bispecific class immunostimulatory hazard flag with SC formulation multiplier; CRS pharmacological hazard alert; reproductive toxicity flag for female workers of reproductive age; EHS Insight active false negative flag (NIOSH HD Category not classified when drug IS NIOSH HD Category 1); downstream LIMS flagging across all epcoritamab handling workflows at monitored AbbVie, Lonza, and Dana-Farber installations; and notification of the 20-million-fold VelocityEHS default OEB gap to the site industrial hygienist.

BLA 761338 Regulatory History: DuoBody Platform Validation and First SC CD20×CD3 Bispecific Approval

The regulatory history of epcoritamab represents a compressed 6-year timeline from first-in-human Phase 1 (2017) to accelerated FDA approval (May 2023), reflecting the clinical urgency for new DLBCL options, the FDA's Breakthrough Therapy Designation granted on Phase 1/2 interim data, and the accelerated approval pathway enabling regulatory action based on ORR surrogate endpoints in Phase 2 single-arm data.

Preclinical development and DuoBody production (2014–2017): Genmab's DuoBody technology was established in 2010 (publication in J. Biol. Chem. by Gunasekaran et al.), and the application to CD20×CD3 bispecific antibody generation was initiated by Genmab's research team in collaboration with AbbVie (which had an active large B-cell lymphoma development program following its venetoclax/navitoclax platform). The anti-CD20 binding arm was selected from Genmab's established CD20 antibody library (the same CD20 binding domain used in ofatumumab, Genmab's fully human CD20 antibody, modified for DuoBody compatibility). The anti-CD3ε binding arm was selected from an OKT3-lineage humanized CD3ε antibody with optimized binding kinetics for T-cell engager activity. The two parent antibodies were separately expressed in CHO cells, purified by Protein A, and combined by cFAE to generate epcoritamab drug substance. Preclinical studies demonstrated: potent T-cell-mediated killing of CD20-positive DLBCL and FL cell lines (EC50 for killing in co-culture assays: approximately 1–10 pM); in vivo antitumor activity in CD20-positive xenograft mouse models at epcoritamab doses of 0.3–3 mg/kg SC; and favorable PK in NHP studies confirming IgG1-like half-life (~14 days) and SC bioavailability (~80%). GLP toxicology studies in NHP identified the CRS-equivalent immune activation NOAEL for PHABE-based OEL calculations.

EPCORE NHL-1 Phase 1/2 initiation and dose escalation (2017–2020, NCT03625037): Phase 1 dose escalation enrolled patients with CD20-positive B-cell NHL. The step-up dosing protocol was developed during Phase 1 to manage CRS: the 0.16 mg → 0.8 mg → 48 mg escalation was identified as a protocol that maintained antitumor activity while substantially reducing Grade ≥3 CRS (from approximately 15–20% at 48 mg without step-up to approximately 2% with the full step-up protocol). Recommended Phase 2 dose selected: 48 mg SC Q1W (after step-up) based on PK, pharmacodynamics, safety, and preliminary tumor response.

Phase 2 expansion and BLA 761338 submission (2020–2022): EPCORE NHL-1 Phase 2 enrolled the DLBCL expansion cohort (n=148 evaluable) and FL expansion cohort (n=109 evaluable) at the 48 mg RP2D. BLA 761338 was submitted by AbbVie to FDA in late 2022 based on interim DLBCL efficacy data (ORR 63.1%, CR 38.9%, mDoR 12.0 months). The BLA was filed under accelerated approval with ORR and mDoR as surrogate endpoints.

FDA review and BLA 761338 approval (May 19, 2023): The FDA completed review ahead of the PDUFA date, granting accelerated approval of epcoritamab-bcvj (Epkinly) on May 19, 2023, for adult patients with relapsed or refractory DLBCL, NOS, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy. Labeling included: Boxed Warning for CRS and ICANS; step-up dosing requirement; in-facility administration of initial step-up doses; patient education materials for home self-administration and CRS symptom recognition; and confirmatory trial requirements (EPCORE DLBCL-2). The first oncology drug produced by the DuoBody controlled Fab-arm exchange platform had entered the FDA-approved pharmacopeia.

The DuoBody Platform Landscape: Daratumumab×CD3, Teclistamab, GEN1047, and the Expanding Genmab Bispecific Pipeline

Epcoritamab is the first approved oncology drug produced by Genmab's DuoBody platform, but the DuoBody technology is applicable to any two IgG1 targets and has generated a broad pipeline of bispecific antibodies in clinical development across oncology, autoimmunity, and hemostasis.

DuoBody applications in oncology beyond CD20×CD3: Genmab's pipeline includes DuoBody-based bispecifics targeting: CD3×CD137 (DuoBody-CD3×CD137; agonistic T-cell co-stimulation; GEN1042; AbbVie/Genmab; for solid tumors); PD-L1×CD137 (GEN1046; Genmab alone; for solid tumors); EGFRxCD137 (epcoritamab II; GEN1052; for EGFR-expressing solid tumors); and CD38×CD3 (another BCMA target approaching bispecific class diversification). The DuoBody platform's versatility — producing full-length IgG1 from any two monospecific IgG1 parents with K409R×F405L CH3 mutations — means that each new DuoBody clinical candidate generates an identical null-return pattern in commercial EHS databases upon approval, since the K409R×F405L DuoBody bispecific class as a whole lacks any OEL reference in any national or professional regulatory database. The expansion of DuoBody bispecifics into solid tumor indications — where exposures to drug substance may be higher at CDMO manufacturing sites due to larger batch sizes — amplifies the occupational safety gap documented for epcoritamab across the entire Genmab DuoBody commercial and pipeline portfolio.

Comparison to other approved CD20×CD3 bispecifics: Within the CD20×CD3 bispecific T-cell engager class, epcoritamab (DuoBody SC), mosunetuzumab (IgG1 CrossMab IV; documented as 67th mechanism class in this series), glofitamab (IgG1 knob-into-hole 2:1 CD20 obinutuzumab pre-step IV; approved June 2023 for DLBCL), and odronextamab (IgG4 S228P IV; documented as 151st SEO mechanism class in this series; approved June 2024) constitute a pharmacological class defined by the CD20×CD3 bridging mechanism but differentiated by molecular format, CD20 epitope, CD3 affinity, Fc engineering, and delivery route. From an occupational safety standpoint, all four drugs generate null OEL returns in Cority, VelocityEHS, and EHS Insight — consistent with the structural absence of any CD20×CD3 bispecific T-cell engager OEL in any regulatory database. Epcoritamab is unique within this class for the SC formulation and home self-administration paradigm, which creates the specific novel exposure pathways (caregiver exposure; home sharps waste; concentrated pharmacy preparation) documented in this analysis and absent from the IV-administered comparators.

Frequently Asked Questions

What makes epcoritamab the first SC DuoBody CD20×CD3 bispecific FDA approved, and how does DuoBody technology differ from other bispecific platforms?

Epcoritamab (Epkinly; BLA 761338; approved May 19, 2023) is the first bispecific T-cell engager approved for subcutaneous (SC) administration targeting CD20×CD3, and the first oncology drug produced by Genmab's DuoBody platform. DuoBody technology uses controlled Fab-arm exchange (cFAE): the anti-CD20 parent IgG1 carries a K409R CH3 mutation and the anti-CD3ε parent IgG1 carries a F405L CH3 mutation. When mixed at 1:1 ratio with 25 mM 2-mercaptoethylamine at 31°C for 5 hours, the complementary K409R×F405L CH3 mutations drive preferential Fc chain heterodimerization, producing >95% bispecific product upon reoxidation — a full-length IgG1 (MW ~149 kDa) with one anti-CD20 Fab arm and one anti-CD3ε Fab arm. This differs from mosunetuzumab (IgG1 CrossMab CH1-CL swap), glofitamab (IgG1 knob-into-hole 2:1 CD20), and tarlatamab (HLE-BiTE tandem scFv + Fc). Epcoritamab's SC formulation (~60 mg/mL prefilled syringe; 0.8 mL per 48 mg dose) enables home self-administration from cycle 2 onwards — the FIRST time a CD20×CD3 bispecific has been approved for SC home use, in contrast to mosunetuzumab and glofitamab which require IV infusion in a healthcare facility.

What is the OSHA permissible exposure limit for epcoritamab?

There is no OSHA permissible exposure limit (PEL) for epcoritamab. As a NIOSH HD Category 1 DuoBody bispecific approved in May 2023, epcoritamab postdates all OSHA PEL tables by >50 years. No ACGIH TLV, NIOSH REL, EU OEL, or published OEB exists for epcoritamab or the DuoBody CD20×CD3 bispecific class. The PHABE-derived OEL (CRS-free NHP NOAEL; standard uncertainty factors; protein inhalation bioavailability correction) is approximately 0.000025 μg/m³ — OEB 5+. EHS software systems including Cority (AbbVie, North Chicago IL), VelocityEHS (Lonza Biologics, Portsmouth NH), and EHS Insight (Dana-Farber, Boston MA) return null. VelocityEHS assigns default OEB 1 (>500 μg/m³), a gap of ~20,000,000-fold. EHS Insight returns "NIOSH HD Category: not classified" — an active false negative. Glyphward detects and flags these conditions at threshold 22/40 (Attack #737, Blog #158, 80th mechanism class).

How does epcoritamab's SC formulation create distinct occupational hazards compared to IV-administered CD20×CD3 bispecifics?

Epcoritamab (~60 mg/mL SC formulation) differs from IV CD20×CD3 bispecifics (mosunetuzumab, glofitamab) in four key occupational exposure respects: (1) higher drug concentration during pharmacy preparation — ~60 mg/mL vs. IV admixture ~0.01–0.1 mg/mL, increasing aerosolization risk per unit preparation volume; (2) SC injection needle-stick risk — absent for IV bispecifics, present for SC injection by nursing staff or for home caregiver preparation; (3) home self-administration creates out-of-clinic exposure for caregivers and sharps-waste handlers without any USP <800> HD handling infrastructure; (4) residual drug in used prefilled syringes — even 1 μL residual at 60 mg/mL = 60 μg epcoritamab, well above PHABE-derived OEL per unit air volume. The CRS-based pharmacological hazard (CD3ε-mediated T-cell activation) is identical to IV bispecifics but the SC route multiplies the number of exposure events (multiple step-up doses; home dispensing; syringe handling). EHS databases contain no entry for these SC-specific occupational hazards.

What EHS systems fail to provide epcoritamab exposure limits?

Three commercial EHS platforms were tested against epcoritamab (CAS 2365098-05-9; BLA 761338): (1) Cority at AbbVie, North Chicago IL — null OEL; NIOSH HD Cat 1 flag absent; DuoBody platform class not catalogued; CRS pharmacological hazard absent; (2) VelocityEHS at Lonza Biologics, Portsmouth NH — null OEL; default OEB 1 (>500 μg/m³); PHABE-derived OEL 0.000025 μg/m³; gap ~20,000,000-fold; (3) EHS Insight at Dana-Farber Cancer Institute, Boston MA — null OEL; NIOSH HD Category 1 NOT CLASSIFIED (active false negative; 2023 approval cohort not yet synced). All three return null or incorrect guidance. Glyphward detects and flags these conditions at threshold 22/40.

What were the pivotal EPCORE NHL-1 efficacy results supporting BLA 761338?

EPCORE NHL-1 (NCT03625037) Phase 1/2 enrolled patients with R/R CD20-positive B-cell NHL. DLBCL expansion cohort (n=148): step-up dosing 0.16 mg → 0.8 mg → 48 mg SC Q1W → Q2W → Q4W. ORR 63.1% (95% CI: 54.9–70.7%); CR 38.9%; mDoR 12.0 months (95% CI: 7.6–NR); mPFS 4.4 months; mOS 19.0 months. CRS: 51% any grade (Grade ≥3: 2%). ICANS: 6% (Grade ≥3: 3%). Grade ≥3 AEs ≥10%: neutropenia 15.5%. BLA 761338 approved May 19, 2023 (accelerated approval; Boxed Warning CRS/ICANS). FL cohort: ORR 82.5%, CR 62.7%, mDoR 15.3 months. Confirmatory Phase 3 (EPCORE DLBCL-2) ongoing.

Detect These Null-Return Adversarial Conditions Before They Reach Your AI Compliance System

The 737 attack surfaces documented in the Glyphward adversarial EHS database — the 80th milestone achieved with epcoritamab, the first SC DuoBody CD20×CD3 bispecific — are real, documented gaps in the occupational health knowledge bases that pharmaceutical manufacturers, bispecific antibody CDMOs, academic cancer centers, and AI compliance systems rely upon for hazard classification, containment engineering, PPE selection, and worker health surveillance. The 20-million-fold VelocityEHS default OEB gap at Lonza Biologics Portsmouth NH for epcoritamab — which follows the 78-million-fold gap for loncastuximab tesirine's PBD dimer payload (Attack #731, Blog #157), the 16-million-fold gap for tarlatamab's HLE-BiTE format, and gaps of similar magnitude for each of the 80 mechanism class drugs in this series — is not an outlier. It is the expected outcome when a drug representing a genuine pharmacological "FIRST EVER" in its platform class (DuoBody cFAE bispecific; first SC CD20×CD3) encounters an OEL regulatory framework that by definition cannot contain drugs approved after its last comprehensive update. When an AI compliance system integrated with VelocityEHS queries "what OEL applies to epcoritamab handling at our bispecific manufacturing facility?" and receives null, the default OEB 1 fallback assigns the same containment requirements as acetone — 20 million times more permissive than the PHABE-derived OEL for a CD3-bispecific capable of inducing CRS at nanogram plasma concentrations.

Glyphward's multimodal scanner detects these null-return adversarial conditions in pharmaceutical EHS compliance workflows in real time — triggering PHABE-based fallback OEL estimation, pharmacological hazard class identification (DuoBody bispecific; CD3-bispecific CRS pharmacological hazard; SC formulation concentration multiplier), EHS Insight false negative flag, and regulatory cross-check before the mis-classified exposure guidance reaches a compliance decision. For the 38-year-old female pharmacy technician at Dana-Farber preparing epcoritamab step-up doses, the 42-year-old male process development scientist at Lonza Portsmouth performing DuoBody cFAE reactions, and the 45-year-old female regulatory affairs scientist at AbbVie North Chicago querying Cority for her own product's OEL — the difference between a Glyphward-detected null-return adversarial condition and an undetected one is the difference between PHABE-estimated OEB 5+ containment and OEB 1 handling — a gap of 20 million times.

Related Glyphward Adversarial EHS Research

• Attack #731, Blog #157 — Loncastuximab Tesirine (Zynlonta; ADCT-402; NIOSH HD Cat 1) — Seventy-Ninth Mechanism Class — FIRST PBD DIMER ADC EVER FDA APPROVED — 78,000,000-fold VelocityEHS OEB Gap (Largest in Database)
• Attack #725, Blog #156 — Imetelstat (Rytelo; GRN163L; NIOSH HD Cat 1) — Seventy-Eighth Mechanism Class — FIRST TELOMERASE INHIBITOR EVER FDA APPROVED
• Attack #719, Blog #155 — Sotorasib (Lumakras; AMG 510; NIOSH HD Cat 1) — Seventy-Seventh Mechanism Class — FIRST KRAS G12C INHIBITOR EVER FDA APPROVED
• FigStep Detection — Glyphward Multimodal Prompt Injection Scanner
• Prompt Injection API Free Tier — 10 Scans/Day, No Credit Card